RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing PseudomonasaeruginosaOprF

Clinical and Experimental Immunology

Volumn 173, Issue 2, 2013, Pages 230-241

  Krause, A ^a   Whu, W Z ^a   Qiu, J ^a   Wafadari, D ^a   Hackett, N R ^a   Sharma, A ^a   Crystal, R G ^a   Worgall, S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

adenovirus; lung; mucosal immunity; pseudomonas; RGD

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BACTERIAL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PSEUDOMONAS AERUGINOSA OPRF; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL SPECIFICITY; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS MACROPHAGE; LUNG INFECTION; MOUSE; MUCOSAL IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; VIRUS CAPSID;

ADENOVIRUS; LUNG; MUCOSAL IMMUNITY; PSEUDOMONAS; RGD;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PORINS; PRIMATES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; TH1 CELLS;

EID: 84879998723     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12101     Document Type: Article

References (71)

1. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 2006; 34:S3-10.
2. Doring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008; 26:1011-1024.
3. Holder IA. Pseudomonas immunotherapy: a historical overview. Vaccine 2004; 22:831-839.
4. Sedlak-Weinstein E, Cripps AW, Kyd JM, Foxwell AR. Pseudomonas aeruginosa: the potential to immunise against infection. Exp Opin Biol Ther 2005; 5:967-982.
5. Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum Vaccin 2011; 7:999-1011.
6. Gilleland HE, Gilleland LB, Fowler MR. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J Med Microbiol 1993; 38:79-86.
7. Price BM, Barten LJ, Galloway DR etal. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 2002; 33:89-99.
8. von Specht BU, Lucking HC, Blum B, Schmitt A, Hungerer KD, Domdey H. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine 1996; 14:1111-1117.
9. Knapp B, Hundt E, Lenz U etal. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine 1999; 17:1663-1666.
10. Mutharia LM, Nicas TI, Hancock RE. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis 1982; 146:770-779.
11. Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004; 22:840-847.
12. Baumann U, Gocke K, Gewecke B, Freihorst J, von Specht BU. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir Res 2007; 8:57.
13. Gocke K, Baumann U, Hagemann H etal. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol 2003; 37:167-171.
14. Hidaka C, Milano E, Leopold PL etal. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999; 103:579-587.
15. Larbig M, Mansouri E, Freihorst J etal. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 2001; 19:2291-2297.
16. Mansouri E, Gabelsberger J, Knapp B etal. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun 1999; 67:1461-1470.
17. Sorichter S, Baumann U, Baumgart A, Walterspacher S, von Specht BU. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. Vaccine 2009; 27:2755-2759.
18. Ding B, von Specht BU, Li Y. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa. Vaccine 2010; 28:4119-4122.
19. Wu L, Estrada O, Zaborina O etal. Recognition of host immune activation by Pseudomonas aeruginosa. Science 2005; 309:774-777.
20. Krause A, Joh JH, Hackett NR etal. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 2006; 80:5523-5530.
21. Krause A, Worgall S. Delivery of antigens by viral vectors for vaccination. Ther Deliv 2011; 2:51-70.
22. Worgall S, Krause A, Rivara M etal. Protection against P.aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 2005; 115:1281-1289.
23. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG. Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P.aeruginosa OprF. J Virol 2007; 81:13801-13808.
24. Okada N, Saito T, Masunaga Y etal. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61:7913-7919.
25. Worgall S, Busch A, Rivara M etal. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 2004; 78:2572-2580.
26. D'Ambrosio E, Del Grosso N, Chicca A, Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hyg (Lond) 1982; 89:155-161.
27. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996; 3:154-162.
28. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006; 24:849-862.
29. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010; 5:386-390.
30. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009; 17:1333-1339.
31. Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, Worgall S. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P.aeruginosa protein OprF. Vaccine 2011; 29:2131-2139.
32. Chen K, Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 2010; 33:479-491.
33. Simon JK, Ramirez K, Cuberos L etal. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin Vaccine Immunol 2011; 18:355-361.
34. Wong-Chew RM, Islas-Romero R, Garcia-Garcia ML etal. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 2006; 24:683-690.
35. Higginson D, Theodoratou E, Nair H etal. An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children. BMC Public Health 2011; 11 (Suppl. 3):S31.
36. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:S45-53.
37. Hersh J, Crystal RG, Bewig B. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther 1995; 2:124-131.
38. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70:7498-7509.
39. Rosenfeld MA, Yoshimura K, Trapnell BC etal. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68:143-155.
40. De B, Heguy A, Leopold PL etal. Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin. Mol Ther 2004; 10:1003-1010.
41. Worgall S, Kikuchi T, Singh R, Martushova K, Lande L, Crystal RG. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P.aeruginosa-pulsed dendritic cells. Infect Immun 2001; 69:4521-4527.
42. Heguy A, Crystal RG. Intrapleural 'outside-in' gene therapy: therapeutics for organs of the chest via gene transfer to the pleura. Curr Opin Mol Ther 2005; 7:440-453.
43. Nieuwenhuis EE, Matsumoto T, Exley M etal. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002; 8:588-593.
44. Appledorn DM, Aldhamen YA, Godbehere S, Seregin SS, Amalfitano A. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity. Clin Vaccine Immunol 2011; 18:150-160.
45. Worgall S, Leopold PL, Wolff G, Ferris B, Van RN, Crystal RG. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997; 8:1675-1684.
46. Zsengeller Z, Otake K, Hossain SA, Berclaz PY, Trapnell BC. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol 2000; 74:9655-9667.
47. Herrera OB, Brett S, Lechler RI. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules - potential benefits in vaccine design. Vaccine 2002; 21:231-242.
48. Harui A, Roth MD, Vira D, Sanghvi M, Mizuguchi H, Basak SK. Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins. J Leukoc Biol 2006; 79:1271-1278.
49. Krause A, Xu Y, Ross S, Wu W, Joh J, Worgall S. Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. Virol J 2011; 8:375.
50. Odaka M, Sterman DH, Wiewrodt R etal. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001; 61:6201-6212.
51. Skaricic D, Traube C, De B etal. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology 2008; 378:79-85.
52. Sterman DH, Recio A, Vachani A etal. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11:7444-7453.
53. Labow D, Lee S, Ginsberg RJ, Crystal RG, Korst RJ. Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum Gene Ther 2000; 11:759-769.
54. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72:4212-4223.
55. Zhang Y, Chirmule N, Gao GP etal. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3:697-707.
56. Inaba K, Turley S, Yamaide F etal. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998; 188:2163-2173.
57. Condon TV, Sawyer RT, Fenton MJ, Riches DW. Lung dendritic cells at the innate-adaptive immune interface. J Leukoc Biol 2011; 90:883-895.
58. Kugathasan K, Roediger EK, Small CL, McCormick S, Yang P, Xing Z. CD11c+ antigen presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and capabilities to activate naive and antigen-primed T cells. BMC Immunol 2008; 9:48.
59. Faith A, Corrigan C, Hawrylowicz C. Dendritic cells, macrophages and monocytes in allergic disease. Allergy Front 2009: 2: 195-207.
60. Harvey BG, Worgall S, Ely S, Leopold PL, Crystal RG. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector. Hum Gene Ther 1999; 10:2823-2837.
61. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003; 10:955-963.
62. Molinier-Frenkel V, Lengagne R, Gaden F etal. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002; 76:127-135.
63. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18:927-974.
64. Hazlett LD, Li Q, Liu J, McClellan S, Du W, Barrett RP. NKT cells are critical to initiate an inflammatory response after Pseudomonas aeruginosa ocular infection in susceptible mice. J Immunol 2007; 179:1138-1146.
65. Shayakhmetov DM, Li ZY, Ternovoi V, Gaggar A, Gharwan H, Lieber A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 2003; 77:3712-3723.
66. Miyazawa N, Crystal RG, Leopold PL. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol 2001; 75:1387-1400.
67. Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: many means to many ends. Adv Drug Deliv Rev 2007; 59:810-821.
68. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012; 18:509-519.
69. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15:194-222.
70. Schaad UB, Buhlmann U, Burger R etal. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 2000; 44:1163-1167.
71. Fisher JT, Zhang Y, Engelhardt JF. Comparative biology of cystic fibrosis animal models. Methods Mol Biol 2011; 742:311-334.